Dugdale Alexandra Ha, Adams Wendy A, Jones Ronald S
University of Liverpool, Department of Anaesthesia, Liverpool, UK.
Vet Anaesth Analg. 2002 Jan;29(1):49-53. doi: 10.1046/j.1467-2987.2001.00057.x. Epub 2016 Nov 15.
The aim of this study was to characterize the onset and duration of action of the aminosteroid muscle relaxant rocuronium in dogs under clinical conditions.
Prospective single dose trial.
Twenty-three dogs aged between 6 months and 12 years, weighing between 5.5 and 61.5 kg admitted to the University of Liverpool Small Animal Hospital between January and March 2000, and undergoing elective surgical procedures under general anaesthesia.
Following induction of general anaesthesia, neuromuscular function was evaluated using train-of-four (TOF) stimulation. An initial dose of 0.4 mg kg rocuronium was administered intravenously (IV) and neuromuscular blockade was monitored by visually assessing the number of responses (twitches) to TOF stimulation (train-of-four count: TOFC). Incremental doses of 0.16 mg kg rocuronium were administered as indicated, when at least two twitches of the TOFC had returned.
Rocuronium (0.4 mg kg) abolished all responses to TOF stimulation in all dogs. The mean time to onset of neuromuscular blockade (complete abolition of all twitches) was 98 ± 52 seconds. Neuromuscular blockade (absence of all twitches to return of all four) lasted 32.3 ± 8.2 minutes. Incremental doses of 0.16 mg kg had a mean duration of action of 20.8 ± 4.9 minutes and up to seven increments were shown to be noncumulative. The effects of rocuronium were readily antagonized with neostigmine and atropine. Small transient increases in arterial blood pressure, which occurred in three dogs after the administration of rocuronium, were the only cardiovascular side-effects observed.
Rocuronium is an effective nondepolarizing neuromuscular blocking agent in the dog, with a rapid onset of neuromuscular block after intravenous administration and an intermediate duration of action.
Rocuronium produced a neuromuscular block with similar characteristics to those obtained with vecuronium, thus apparently offering little advantage over vecuronium. However, its availability in aqueous solution and a longer shelf-life increases convenience.
本研究旨在描述在临床条件下氨基甾体类肌肉松弛剂罗库溴铵在犬体内的起效时间和作用持续时间。
前瞻性单剂量试验。
2000年1月至3月间收治于利物浦大学小动物医院的23只犬，年龄在6个月至12岁之间，体重在5.5至61.5千克之间，均接受全身麻醉下的择期手术。
全身麻醉诱导后，使用四个成串刺激（TOF）评估神经肌肉功能。静脉注射初始剂量0.4毫克/千克罗库溴铵，通过肉眼评估对TOF刺激的反应（抽搐）次数（四个成串刺激计数：TOFC）来监测神经肌肉阻滞情况。当TOFC至少恢复两个抽搐时，按指示给予递增剂量0.16毫克/千克罗库溴铵。
罗库溴铵（0.4毫克/千克）使所有犬对TOF刺激的反应全部消失。神经肌肉阻滞起效（所有抽搐完全消失）的平均时间为98±52秒。神经肌肉阻滞（从所有抽搐消失到全部四个抽搐恢复）持续32.3±8.2分钟。递增剂量0.16毫克/千克的平均作用持续时间为20.8±4.9分钟，显示多达七次递增剂量无累积效应。罗库溴铵的作用可被新斯的明和阿托品轻易拮抗。给药后三只犬出现动脉血压短暂小幅升高，这是观察到的唯一心血管副作用。
罗库溴铵是犬体内一种有效的非去极化神经肌肉阻滞剂，静脉注射后神经肌肉阻滞起效迅速，作用持续时间中等。
罗库溴铵产生的神经肌肉阻滞特征与维库溴铵相似，因此与维库溴铵相比显然优势不大。然而，其水溶液的可用性和更长的保质期增加了便利性。
